Practical management of behavioral problems in mucopolysaccharidoses disorders. (Q47571355)

4 February 2018

title

Practical management of behavioral problems in mucopolysaccharidoses disorders. (English)

1 reference

4 February 2018

author name string

Maria L Escolar

1

1 reference

4 February 2018

Simon A Jones

2

1 reference

4 February 2018

Elsa G Shapiro

3

1 reference

4 February 2018

Dafne D G Horovitz

4

1 reference

4 February 2018

Christina Lampe

5

1 reference

4 February 2018

Hernán Amartino

6

1 reference

4 February 2018

publication date

27 September 2017

1 reference

4 February 2018

Molecular Genetics and Metabolism

published in

1 reference

4 February 2018

volume

122S

1 reference

4 February 2018

page(s)

35-40

1 reference

4 February 2018

Overview of the mucopolysaccharidoses

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Brain and spinal MR imaging findings in mucopolysaccharidoses: a review.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

The mucopolysaccharidoses: a heterogeneous group of disorders with variable pediatric presentations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Intellectual and neurological functioning in Morquio syndrome (MPS IVa).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Behaviour in mucopolysaccharide disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Why are behaviors of children suffering from various neuronopathic types of mucopolysaccharidoses different?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Natural progression of neurological disease in mucopolysaccharidosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Neurocognition across the spectrum of mucopolysaccharidosis type I: Age, severity, and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Degeneration of speech, language, and hearing in a patient with mucopolysaccharidosis VII.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Heparan sulfate saccharides modify focal adhesions: implication in mucopolysaccharidosis neuropathophysiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Neuropathology in mouse models of mucopolysaccharidosis type I, IIIA and IIIB

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Behavioural phenotypes of the mucopolysaccharide disorders: a systematic literature review of cognitive, motor, social, linguistic and behavioural presentation in the MPS disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Challenging symptoms in children with rare life-limiting conditions: findings from a prospective diary and interview study with families.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Management of the behavioural manifestations of Hunter syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Pathophysiology, evaluation, and management of sleep disorders in the mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Multidisciplinary management of Hunter syndrome.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Psychosocial problems in Hunter's syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Is Sanfilippo type B in your mind when you see adults with mental retardation and behavioral problems?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Mucopolysaccharidosis Type IIIA presents as a variant of Klüver-Bucy syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

The Neurobehavioral Phenotype in Mucopolysaccharidosis Type IIIB: an Exploratory Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Sleep disturbance in Sanfilippo syndrome: a parental questionnaire study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Sleep problems in children with Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Early clinical markers of central nervous system involvement in mucopolysaccharidosis type II.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Assessment of sleep in children with mucopolysaccharidosis type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Sleep apnea and the risk of dementia: a population-based 5-year follow-up study in Taiwan

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Natural history of Sanfilippo syndrome type A.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

A Prospective Natural History Study of Mucopolysaccharidosis Type IIIA.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Parental social support, coping strategies, resilience factors, stress, anxiety and depression levels in parents of children with MPS III (Sanfilippo syndrome) or children with intellectual disabilities (ID).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Management of mucopolysaccharidosis type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Cerebrospinal fluid shunts in the management of behavioural problems in Sanfilippo syndrome (MPS III).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Epileptic seizures and epilepsy: definitions proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Nocturnal frontal lobe epilepsy in mucopolysaccharidosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Disordered breathing during sleep in patients with mucopolysaccharidoses.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Behavioural interventions for children and adults with behaviour disorders after TBI: a systematic review of the evidence

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Acquired autistic behaviors in children with mucopolysaccharidosis type IIIA

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Clinical overview of children with mucopolysaccharidosis type III A and effect of Risperidone treatment on children and their mothers psychological status

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Extrapyramidal symptoms and medication use in Mucopolysaccharidosis type III.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Estrogens control aggressive behavior in some patients with Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Treatment of psychomotor agitation and self-injurious behavior with estrogen and progesterone in a patient with Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Estrogen actions throughout the brain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Impairment of the melatonin rhythm in children with Sanfilippo syndrome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Sleep disturbance in mucopolysaccharidosis type III (Sanfilippo syndrome): a survey of managing clinicians

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

Triple P-Positive Parenting Program: towards an empirically validated multilevel parenting and family support strategy for the prevention of behavior and emotional problems in children

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMGME.2017.09.010

10.1016/J.YMGME.2017.09.010

7 January 2021

Identifiers

DOI

1 reference

4 February 2018

PubMed ID

29170079

1 reference

4 February 2018